rs1898830 — TLR2

Intronic TLR2 variant that modulates innate immune signaling intensity; G allele reduces TLR2 pathway activity and is protective against tuberculosis and periodontitis, while the common A allele sustains higher TLR2 activation linked to cardiovascular risk markers and autoimmune inflammation

See your personal result for TLR2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

TLR2 rs1898830 — When Innate Immune Vigilance Tips into Autoimmune Fire

Toll-like receptor 2 (TLR2)11 Toll-like receptor 2 (TLR2)
A pattern recognition receptor on the surface of macrophages, dendritic cells, and T regulatory cells that detects bacterial lipoproteins, peptidoglycans, and endogenous danger signals released from damaged tissue occupies a pivotal position in innate immunity: it sounds the alarm when bacteria arrive, but also mediates chronic inflammation when tissue damage keeps feeding it self-derived signals. The rs1898830 variant sits within the first intron of TLR2 on chromosome 4, and while it does not change the receptor's amino acid sequence, evidence from population studies suggests it modulates TLR2 signaling intensity — with effects that ripple into autoimmune disease risk, infection susceptibility, and cardiovascular physiology.

The A allele is the more common form globally (~69% frequency), meaning roughly 47% of people carry two copies (AA) and represent the baseline signaling state. The rarer G allele (~31% globally) appears to reduce TLR2-mediated cellular activation, conferring protection against tuberculosis and periodontitis while simultaneously modulating cardiovascular risk markers in the opposite direction — illustrating the double-edged nature of innate immune tuning.

The Mechanism

rs1898830 (NC_000004.12:g.153687301A>G) is an intronic variant annotated in multiple transcripts of TLR2. Since it lies outside the coding exons, its functional effect is indirect. Research in COPD populations found the variant associated with TLR2-mediated cellular activation, and mechanistic studies propose that rs1898830 acts primarily through linkage disequilibrium with rs1315033122 linkage disequilibrium with rs13150331
A SNP in the 5′-flanking promoter region of TLR2 that directly affects transcriptional activity of the gene; rs1898830 and rs13150331 are in strong LD, so the intronic variant tags the promoter signal. The A haplotype is associated with sustained or higher TLR2 promoter activity, while the G haplotype tags reduced transcriptional output.

Why does lower TLR2 signaling protect against bacterial pathogens in some contexts? The answer lies in how TLR2 governs the balance between innate immune clearance and resolution. TLR2 heterodimerizes with TLR1 or TLR633 TLR2 heterodimerizes with TLR1 or TLR6
This dimerization determines which ligands TLR2 can detect: TLR2/TLR1 recognizes triacylated lipopeptides from Gram-positive bacteria; TLR2/TLR6 recognizes diacylated lipopeptides from mycoplasma and signals through MyD88 to activate NF-κB and trigger pro-inflammatory cytokine production. Sustained high-level TLR2 signaling — as in the A allele haplotype — biases immune cells toward chronic inflammation rather than efficient pathogen clearance.

In the autoimmune context, excessive TLR2 activation is particularly problematic because TLR2 is preferentially expressed on T regulatory cells (Tregs)44 T regulatory cells (Tregs)
A subset of CD4+ T cells that normally suppress excessive immune responses; TLR2 stimulation in MS patients shifts Tregs toward a pro-inflammatory Th17-like phenotype, diminishing their suppressive function. This Treg-to-Th17 skewing appears to be a key driver of autoimmune flares in multiple sclerosis.

The Evidence

The most striking feature of rs1898830's evidence profile is directional consistency across very different bacterial-sensing contexts. In Chinese Han and Tibetan populations, the G allele is protective against pulmonary tuberculosis: the Han study Miao et al. (2015)55 Miao et al. (2015) found the G allele (OR 0.84, p=0.035) and GG genotype (OR 0.72, p=0.042) both reduce TB risk in 599 participants. This was independently replicated in Tibetan Chinese by Xue et al. (2018)66 Xue et al. (2018), where GA genotype had OR 0.70 (p=0.009) against TB susceptibility.

In periodontitis — a chronic infection-driven inflammatory disease — the same protective pattern holds. A meta-analysis by Shan et al. (2020)77 periodontitis — a chronic infection-driven inflammatory disease — the same protective pattern holds. A meta-analysis by Shan et al. (2020) pooled 18 studies (3,873 cases, 3,438 controls) and found GG genotype reduces chronic periodontitis risk by roughly 32% compared to AA (OR 0.68, p=0.014). The A allele carries a statistically significant 21% higher risk per copy (OR 1.21).

Intrauterine CMV transmission adds another dimension. Among 83 Israeli women with second-trimester primary CMV infection, no GG carriers transmitted the virus to the fetus88 no GG carriers transmitted the virus to the fetus
OR 0.00 in recessive model; p=0.008, supporting that G/G reduced TLR2 activation dampens the cytokine milieu that facilitates transplacental CMV passage.

On the cardiovascular side, the pleiotropic nature of TLR2 signaling becomes apparent: in a Lebanese cohort (n=460), Azizi et al. (2020)99 Azizi et al. (2020) found GG genotype associated with 2.18-fold increased hypertension risk (p=0.03) and 33% lower HDL-C (p=0.05) compared to AA. This paradox — protective against infections but associated with cardiometabolic risk markers in the GG group — likely reflects altered macrophage polarization in vascular tissue when TLR2 signaling is constitutively dampened, allowing lipid accumulation without inflammatory clearance signals.

Practical Implications

For AA genotype carriers (the most common genotype), the actionable concern centers on autoimmune inflammation: sustained higher TLR2 pathway activity increases susceptibility to dysregulated Treg function, heightened Th17 responses, and the chronic inflammatory state underlying conditions like MS, rheumatoid arthritis, and periodontal disease. Periodic dental assessment and awareness of systemic inflammatory markers are the most immediately actionable steps. For cardiovascular health, AA carriers appear to have more favorable HDL and blood pressure profiles than GG homozygotes.

For AG heterozygotes, the picture is intermediate across all these dimensions.

For GG homozygotes, the key insight is that reduced TLR2 activation provides resilience against bacterial-driven inflammatory diseases, but the same dampened signaling may reduce clearance of some pathogens and — in vascular tissue — contribute to cardiometabolic risk. Monitoring HDL levels and blood pressure is warranted.

Interactions

TLR2 does not function in isolation at the chromosome 4 cluster. Two well-characterized TLR2 variants are already in the GeneOps database: rs46964801010 rs4696480
TLR2 promoter -16934T/A variant with strong associations with atopic dermatitis and psoriasis; A allele increases promoter activity, in partial LD with rs1898830 and rs38040991111 rs3804099
TLR2 synonymous coding variant with immune phenotype associations. Haplotypes combining multiple TLR2 variants in strong LD may have compounded effects on TLR2 signaling levels and downstream autoimmune risk that exceed any single variant's effect.

TLR4 (rs4986790, Asp299Gly) in the same innate immunity pathway blunts responses to Gram-negative bacteria. Individuals carrying dampened-signaling variants at both TLR2 (rs1898830 G) and TLR4 (rs4986790 G) may have substantially reduced innate pattern recognition capacity — a profile with implications for bacterial clearance, sepsis risk, and the microbiome-driven immune tone that regulates autoimmune susceptibility.

Genotype Interpretations

What each possible genotype means for this variant.

AA Normal

Common TLR2 signaling state with typical innate immune activation

You carry two copies of the A allele, the most common form globally. About 47% of people share this genotype. Your TLR2 pathway operates at the reference signaling level, with no reduction in ligand-induced cellular activation. Studies suggest this baseline TLR2 activity carries lower cardiovascular risk markers (better HDL profile, lower hypertension risk) compared to GG carriers, while also sustaining the higher innate immune tone associated with autoimmune inflammatory phenotypes.

AG Intermediate

One G allele — moderately reduced TLR2 signaling with partial protective effect against infection-driven inflammation

The G allele at rs1898830 appears to tag a haplotype that reduces TLR2 transcriptional activity via the nearby promoter SNP rs13150331. In heterozygous form, only one of your two TLR2 gene copies carries this reduced-activity haplotype, resulting in intermediate signaling. Meta-analysis data from over 7,000 periodontitis cases and controls shows that this intermediate genotype provides partial but significant protection against chronic periodontitis compared to AA (allele model OR 0.83, recessive model partially applying). In TB studies, even single G allele carriage shifts risk modestly toward protection.

The balance between infection defense and autoimmune risk runs through TLR2 signaling tone — one G allele partially shifts this balance toward less chronic inflammatory drive without fully suppressing pathogen recognition.

GG Decreased

Reduced TLR2 pathway activation — protective against infection-driven inflammation but associated with cardiometabolic risk markers

The GG genotype represents the maximal shift toward reduced TLR2 signaling across both gene copies. This creates a coherent biological picture: lower TLR2-driven NF-κB activation means less chronic pro-inflammatory cytokine output in response to bacterial ligands and danger signals. In tissues where persistent TLR2 activation drives destructive inflammation — periodontium, TB-infected lungs — this is protective. In vascular tissue, where TLR2 signaling helps orchestrate lipid processing by macrophages, reduced signaling may impair reverse cholesterol transport (lowering HDL) and alter vascular tone (raising blood pressure).

The CMV transmission finding is especially notable: the protective effect was specific to second-trimester infection (0% transmission in GG mothers vs ~40% in AA/AG), suggesting TLR2-mediated immunological events in mid-pregnancy play a specific role in controlling placental viral passage.

In the autoimmunity context, the reduced TLR2 tone of GG carriers is theoretically advantageous — less Treg-to-Th17 skewing, less TLR2-driven oligodendrocyte progenitor inhibition in the brain — but clinical autoimmune disease association studies specifically for GG carriers of rs1898830 have not been published.